Brand names: GIVLAARI
12.1 Mechanism of Action Givosiran is a double-stranded small interfering RNA that causes degradation of aminolevulinate synthase 1 ( ALAS1 ) mRNA in hepatocytes through RNA interference, reducing the elevated levels of liver ALAS1 mRNA. This leads to reduced circulating levels of neurotoxic intermediates aminolevulinic acid (ALA) and porphobilinogen (PBG), factors associated with attacks and other disease manifestations of AHP.
6 documented side effects by frequency
No community discussions found for GIVOSIRAN SODIUM yet.
Every figure on this page links back to its primary source. See data sources for full provenance.
0 available comparisons
No comparisons yet.
Dosage Forms
Tablet
Route
Subcutaneous